Alliancebernstein L.P. reduced its position in Epizyme (NASDAQ:EPZM) by 9.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 38,200 shares of the biopharmaceutical company’s stock after selling 4,200 shares during the period. Alliancebernstein L.P. owned about 0.06% of Epizyme worth $479,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. grew its stake in Epizyme by 42.5% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 217,168 shares of the biopharmaceutical company’s stock worth $4,138,000 after acquiring an additional 64,721 shares during the period. Landscape Capital Management L.L.C. purchased a new stake in Epizyme in the 4th quarter worth approximately $641,000. Spark Investment Management LLC purchased a new stake in Epizyme in the 4th quarter worth approximately $592,000. Hudson Bay Capital Management LP purchased a new stake in Epizyme in the 4th quarter worth approximately $1,569,000. Finally, Peregrine Capital Management LLC purchased a new stake in Epizyme in the 4th quarter worth approximately $6,275,000. 85.83% of the stock is owned by hedge funds and other institutional investors.
Shares of EPZM opened at $15.90 on Tuesday. The firm has a market capitalization of $1,080.44, a price-to-earnings ratio of -7.29 and a beta of 1.95. Epizyme has a fifty-two week low of $9.30 and a fifty-two week high of $21.40.
Several analysts have commented on EPZM shares. ValuEngine cut shares of Epizyme from a “sell” rating to a “strong sell” rating in a research note on Monday, April 9th. Morgan Stanley started coverage on shares of Epizyme in a research note on Wednesday, January 10th. They issued an “overweight” rating and a $20.00 target price for the company. Wedbush reaffirmed an “outperform” rating and issued a $25.00 target price (down from $26.00) on shares of Epizyme in a research note on Wednesday, March 14th. BidaskClub raised shares of Epizyme from a “hold” rating to a “buy” rating in a research note on Thursday, March 15th. Finally, Leerink Swann lifted their target price on shares of Epizyme from $22.00 to $24.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $23.50.
In other Epizyme news, COO Matthew Ros sold 72,264 shares of Epizyme stock in a transaction on Monday, February 5th. The shares were sold at an average price of $16.63, for a total value of $1,201,750.32. Following the transaction, the chief operating officer now owns 74,867 shares in the company, valued at approximately $1,245,038.21. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 21.50% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This story was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://stocknewstimes.com/2018/04/17/epizyme-epzm-holdings-reduced-by-alliancebernstein-l-p.html.
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.